Kuntz L, Noel G, Antoni D
Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de-la-Porte de l'Hôpital, 67065 Strasbourg, France.
Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de-la-Porte de l'Hôpital, 67065 Strasbourg, France; CNRS, IPHC UMR 7178, centre Paul-Strauss, université de Strasbourg, Unicancer, 67000 Strasbourg, France.
Cancer Radiother. 2018 Oct;22(6-7):647-652. doi: 10.1016/j.canrad.2018.07.135. Epub 2018 Sep 6.
Glioblastoma is the most frequent primary brain tumor, with more than half of all patients being at least 65 years old. The treatment of the elderly in this pathology represents therefore a considerable challenge for oncologists and radiation therapists. However, in most clinical trials, age is a non-eligible criterial. In the last ten years, geriatric therapeutic trials have been multiplied. The treatment of glioblastoma consists of adjuvant chemoradiotherapy. In elderly patients, the evaluation of performans status and the molecular characteristics of the tumor are important factors in order to propose the appropriate treatment in terms of efficacy and toxicity.
胶质母细胞瘤是最常见的原发性脑肿瘤,超过半数的患者年龄至少为65岁。因此,针对这种病症对老年人进行治疗,对肿瘤学家和放射治疗师来说是一项相当大的挑战。然而,在大多数临床试验中,年龄是一个不合格标准。在过去十年中,老年治疗试验成倍增加。胶质母细胞瘤的治疗包括辅助放化疗。对于老年患者,评估其身体状况和肿瘤的分子特征是重要因素,以便在疗效和毒性方面提出合适的治疗方案。